Altrinsic Global Advisors LLC Acquires Shares of 21,957 Forty Seven Inc (NASDAQ:FTSV)

Altrinsic Global Advisors LLC acquired a new position in shares of Forty Seven Inc (NASDAQ:FTSV) in the first quarter, HoldingsChannel.com reports. The institutional investor acquired 21,957 shares of the company’s stock, valued at approximately $355,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. PNC Financial Services Group Inc. acquired a new stake in Forty Seven during the first quarter worth approximately $32,000. BNP Paribas Arbitrage SA acquired a new stake in Forty Seven during the first quarter worth approximately $48,000. Citigroup Inc. grew its stake in Forty Seven by 173.8% during the first quarter. Citigroup Inc. now owns 4,189 shares of the company’s stock worth $68,000 after purchasing an additional 2,659 shares during the period. Essex Investment Management Co. LLC acquired a new stake in Forty Seven during the fourth quarter worth approximately $70,000. Finally, New York State Common Retirement Fund acquired a new stake in Forty Seven during the fourth quarter worth approximately $101,000. Institutional investors own 47.34% of the company’s stock.

FTSV has been the subject of a number of research reports. Roth Capital initiated coverage on Forty Seven in a research note on Wednesday, May 29th. They issued a “buy” rating and a $28.00 price objective for the company. Zacks Investment Research raised Forty Seven from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a research note on Tuesday, May 14th. HC Wainwright set a $21.00 price objective on Forty Seven and gave the company a “buy” rating in a research note on Tuesday, May 14th. Guggenheim initiated coverage on Forty Seven in a research note on Friday, April 12th. They issued a “buy” rating for the company. Finally, Oppenheimer reissued a “buy” rating on shares of Forty Seven in a research note on Tuesday, March 19th. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. Forty Seven has an average rating of “Buy” and an average price target of $26.89.

Shares of Forty Seven stock opened at $10.81 on Thursday. Forty Seven Inc has a 52 week low of $10.34 and a 52 week high of $23.83. The company has a market capitalization of $353.73 million and a price-to-earnings ratio of -2.88.

Forty Seven (NASDAQ:FTSV) last announced its earnings results on Monday, May 13th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($0.14). Equities research analysts expect that Forty Seven Inc will post -2.72 EPS for the current fiscal year.

In related news, insider Chris H. Takimoto sold 8,000 shares of Forty Seven stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $16.39, for a total transaction of $131,120.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Mark Anthony Mccamish sold 16,500 shares of Forty Seven stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $12.10, for a total value of $199,650.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 169,811 shares of company stock worth $2,921,746. 37.40% of the stock is owned by insiders.

ILLEGAL ACTIVITY WARNING: This article was first published by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this article on another site, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this article can be viewed at https://transcriptdaily.com/2019/06/13/altrinsic-global-advisors-llc-acquires-shares-of-21957-forty-seven-inc-nasdaqftsv.html.

About Forty Seven

Forty Seven Inc, a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody.

Further Reading: What is the yield curve?

Want to see what other hedge funds are holding FTSV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Forty Seven Inc (NASDAQ:FTSV).

Institutional Ownership by Quarter for Forty Seven (NASDAQ:FTSV)

Receive News & Ratings for Forty Seven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forty Seven and related companies with MarketBeat.com's FREE daily email newsletter.